The substantial buyback at $5.00 per share (a 23% reduction in shares) signals strong insider confidence and may support near-term price stability. Monitor for any subsequent insider transactions or changes in Roivant's stake, as their proportionate tender suggests continued alignment.
Price Chart
Executive Summary
Arbutus Biopharma completed a modified Dutch auction tender offer, repurchasing 46 million shares for $230 million at $5.00 per share, representing ~23% of outstanding shares. The offer was oversubscribed, with proration applied to tenders. Roivant Sciences maintained its ~19.5% stake via proportionate tender. This large buyback signals management's confidence in undervaluation and returns significant capital to shareholders.
Key Financial Metrics
Key Facts
- Arbutus repurchased 46,000,000 shares at $5.00 per share for an aggregate purchase price of $230 million.
- The offer represented approximately 23% of total issued and outstanding shares as of September 29, 2026.
- The tender offer was oversubscribed; auction tenders at or below $5.00 were prorated at approximately 55.6%.
- Roivant Sciences Ltd., beneficial owner of ~19.5% of shares, made a proportionate tender and maintained its ownership percentage.
- Payment and settlement expected on or about October 5, 2026.
- Following completion, approximately 153,275,907 shares will be issued and outstanding.
Financial Impact
$230 million returned to shareholders via share repurchase, reducing share count by ~23%.
Risk Factors
- The buyback reduces cash reserves by $230 million, which could impact funding for clinical programs (imdusiran, AB-101) if capital is needed.
- Oversubscription and proration may disappoint some shareholders who wanted to sell more shares.
- Clinical-stage biotech risk: pipeline setbacks could offset the positive capital return signal.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372775 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $4.21 | awaiting T+60 | awaiting T+60 | $4.29 (+1.90%) |
Oct 22, 2026 5d ago | Press Release | $4.21 | awaiting T+60 | awaiting T+60 | $4.29 (+1.90%) |
Oct 7, 2026 20d ago | SC 13G/A | $4.18 | awaiting T+60 | awaiting T+60 | $4.29 (+2.63%) |
Oct 5, 2026 22d ago | SC 13D/A | $4.48 | awaiting T+60 | awaiting T+60 | $4.29 (−4.24%) |
Oct 1, 2026 26d ago | SC TO-I/A | $4.56 | awaiting T+60 | awaiting T+60 | $4.29 (−5.92%) |
Oct 1, 2026 26d ago | Press Release | $4.56 | awaiting T+60 | awaiting T+60 | $4.29 (−5.92%) |
Sep 30, 2026 27d ago | SC TO-I/A | $4.78 | awaiting T+60 | awaiting T+60 | $4.29 (−10.25%) |
Sep 30, 2026 27d ago | Press Release | $4.78 | awaiting T+60 | awaiting T+60 | $4.29 (−10.25%) |
Aug 21, 2026 9w ago | 8-K | $5.21 | awaiting T+60 | awaiting T+60 | $4.29 (−17.66%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.71 | awaiting T+60 | awaiting T+60 | $4.29 (−8.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers